Biomarkers

A neo-epitope fragment of type I collagen generated by MMP activity, quantifying pathological soft tissue destruction and extracellular matrix turnover.

A matrix metalloproteinase-generated fragment of type III collagen, reflecting extracellular matrix remodeling and enabling assessment of fibrotic activity.

A neo-epitope fragment of type IV collagen generated by matrix metalloproteinase activity, enabling non-invasive assessment of basement membrane degradation and extracellular matrix remodeling in chronic inflammatory and fibrotic diseases.

A cross-linked fragment of type III collagen generated by matrix metalloproteinase activity, enabling non-invasive assessment of fibrolysis and fibrosis resolution.

A bioactive fragment of type VI collagen known as Endotrophin quantifying the intact 77-amino-acid Endotrophin signaling hormone, enabling non-invasive quantification of fibro-inflammatory signaling and risk stratification in chronic disease and oncology.

A neo-epitope fragment of type III collagen released during extracellular matrix remodeling, enabling non-invasive quantification of active fibrogenesis and dynamic assessment of fibrosis progression and treatment response.

A fragment of C-terminal type VIa3 collagen (Endotrophin), enabling non-invasive quantification of fibrogenesis, tissue remodeling and wound healing across chronic diseases.

A matrix metalloproteinase-generated neo-epitope fragment of type I collagen, enabling non-invasive assessment of extracellular matrix degradation and mortality risk in cardiovascular disease.

A neo-epitope fragment of type III collagen generated by fibroblast activation protein (FAP) activity, enabling non-invasive assessment of fibroblast-driven extracellular matrix remodeling in fibrotic and oncologic conditions.

Canstatin, released NC1 domain of type IV collagen a2 chain, enabling non-invasive monitoring of angiogenesis and extracellular matrix remodeling in pathological conditions such as cancer and fibrotic diseases.